Article
MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
The Journal of clinical investigation - 1 May 2013
Schlegel Jennifer, Sambade Maria J, Sather Susan, Moschos Stergios J, Tan Aik-Choon, Winges Amanda, DeRyckere Deborah, Carson Craig C, Trembath Dimitri G, Tentler John J, Eckhardt S Gail, Kuan Pei-Fen, Hamilton Ronald L, Duncan Lyn M, Miller C Ryan, Nikolaishvili-Feinberg Nana, Midkiff Bentley R, Liu Jing, Zhang Weihe, Yang Chao, Wang Xiaodong, Frye Stephen V, Earp H Shelton, Shields Janiel M, Graham Douglas K
Abstract excerpt
Metastatic melanoma is one of the most aggressive forms of cutaneous cancers. Although recent therapeutic advances have prolonged patient survival, the prognosis remains dismal. C-MER proto-oncogene tyrosine kinase (MERTK) is a receptor tyrosine kinase with oncogenic properties that is often over...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.